NasdaqHealth CareHealth Care EquipmentS&P 500Nasdaq-100
$676.04
+5.33 (+0.79%)
Close of Nov 06, 2026 · end-of-day data
IDXX 8-K filings in 2024
Every material Form 8-K Idexx Laboratories filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IDEXX's board approved a new unfunded deferred compensation plan on December 6, 2024, letting select management and highly compensated employees defer part of their pay. The filing describes the plan's terms but gives no financial figures for its cost or expected size, and it is a compensation arrangement rather than a change in leadership.
Board approved the IDEXX Deferred Compensation Plan on December 6, 2024, on the Compensation and Talent Committee's recommendation.
Participants may defer 5% to 50% of base salary and 5% to 100% of annual bonus and stock units.
The Company has no current intention to make discretionary contributions to participant accounts.
Full plan document will be filed as an exhibit to the 2024 Form 10-K.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Idexx Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →